Cutaneous lupus erythematosus after treatment with paclitaxel and bevacizumab for metastatic breast cancer: a case report
2011

Skin Reaction After Cancer Treatment

Sample size: 1 publication Evidence: low

Author Information

Author(s): Vihinen Pia, Paija Outi, Kivisaari Atte, Koulu Leena, Aho Heikki

Primary Institution: Turku University Hospital

Hypothesis

Can paclitaxel and bevacizumab cause cutaneous lupus erythematosus in patients without a history of autoimmune disorders?

Conclusion

Cutaneous lupus erythematosus can occur in patients without prior autoimmune disorders after treatment with paclitaxel and bevacizumab.

Supporting Evidence

  • Paclitaxel and bevacizumab are commonly used in cancer treatment.
  • Skin disorders are rare side effects of these drugs.
  • The patient had no prior autoimmune history.

Takeaway

One woman developed a skin condition after cancer treatment, even though she had no previous skin problems. Stopping the treatment made her skin better.

Methodology

Case report of a 65-year-old woman treated with paclitaxel and bevacizumab for metastatic breast cancer.

Limitations

Only one case is reported, limiting generalizability.

Participant Demographics

65-year-old Caucasian woman.

Digital Object Identifier (DOI)

10.1186/1752-1947-5-243

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication